PharmaTutor (November - 2017)
ISSN: 2347 - 7881
(Volume 5, Issue 11)
Received On: 20/06/2017; Accepted On: 10/07/2017; Published On: 01/11/2017
AUTHORS:
Munish Thakur*, Anupama Setia, Neetu
Department of Pharmaceutical Management & drug regulatory affairs,
JCDM college of pharmacy,
Sirsa, Haryana, India
* munish.thakur98@gmail.com
ABSTRACT:
The drug designated for production has to be manufactured in compliance with Current Good Manufacturing Practices (cGMP) following USFDA requirements, EU Directive or International Conference on Harmonization (ICH) Guidelines or Regulatory Authority of respective country. Regulatory authorities bear the responsibility to conduct inspections on pharmaceutical manufacturing plants to ensure they follows cGMP guidelines so that the drug manufactured is safe and effective. A quality system has to be set up such that the drug is manufactured in accordance with approved procedures. A drug is not permitted for sale until the marketing application for the new drug has been reviewed and approved by regulatory authorities. Extensive dossiers are provided to the authorities to demonstrate the safety, potency, efficacy and purity of the drug. After the drug has been approved and marketed, there is continuous monitoring of the safety and performance of the drug to ensure that it is prescribed correctly and adverse events (side effects) are investigated. The United States Food and Drugs Administration (FDA) has one of the most comprehensive and transparent regulatory systems in the world. In US Common Technical Document (CTD) format and most recently its electronic version-the electronic Common Technical Document (eCTD) format is used for submission of dossiers. Inclusion of a paragraph IV certification permits the Applicant to file its ANDA 4 years after the approval of a new chemical entity that is 1 year before the actual expiry of the 5 years exclusivity. In case patent exists that claims the drug, drug product, or method of use, the applicant is requested to file a patent certification with regards to the patent status. The different types of patent certifications are discussed. This project work elucidates US FDA’s previous interpretations of the statute regarding 180 days exclusivity and latest amendments in the current guidance. Information considered helpful in the compilation of different CTD modules 1, 2, 3, and 5 is discussed. Electronic submission in eCTD format is outlined.
How to cite this article: Thakur M, Setia A, Neetu; An Approval to manufacture and sale the copy of innovator product in the US Market; PharmaTutor; 2017; 5(11); 9-16
[ABSTRACT WITH CITATION] [VIEW AS HTML]
.png)
